Alamab Therapeutics
Princeton, US · Founded 2017 · Delaware corporation
Alamab Therapeutics is a biotechnology company developing therapeutics for acute spinal cord injury (ALMB-0166) and bone-involved cancers (ALMB-0168). It operates in the drug development / therapeutics industry.
Founders & leadership
YZ
YANFENG ZHANGPresident
QW
QINGXI WANGDirector, Chief Executive Officer and Secretary
JS
JUMIN SUNNamed on SEC filing
JX
JEAN X. JIANGNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$11.8M disclosed across 1 round · 2017
▶$11.8MraisedAug 2017 · 1 investors · BiotechnologyRule 506(b)
▶$11.8MraisedAug 2017 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- JUMIN SUNDirector
- JEAN X. JIANGDirector
- YANFENG ZHANGExecutive Officer
- QINGXI WANGExecutive Officer, Director
- Offering amount
- $47.4M
- Amount sold
- $11.8M
- First sale
- Jul 2017
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Alamab Therapeutics do?
- Alamab Therapeutics is a biotechnology company developing therapeutics for acute spinal cord injury (ALMB-0166) and bone-involved cancers (ALMB-0168). It operates in the drug development / therapeutics industry.
- How much funding has Alamab Therapeutics raised?
- Alamab Therapeutics has disclosed $11.8M raised across 1 round.
- Where is Alamab Therapeutics headquartered?
- Alamab Therapeutics is headquartered in Princeton, US.